Oncotelic Therapeutics, Inc. — fact timeline

Oncotelic Therapeutics, Inc. issued a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of common stock to Autotelic, Inc..

“In connection with the Asset Transfer Agreement described in Item 1.01 above, the Company has agreed to issue to Autotelic, Inc. a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of Oncotelic Therapeutics, Inc. with the issuance conditioned on an uplisting of its capital stock to NYSE/NASDAQ.”

Oncotelic Therapeutics, Inc. completed an acquisition involving Lunai Bioworks, Inc. for aggregate stated value of $20,000,000 (closed 2026-05-01).

“greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings”

Oncotelic Therapeutics, Inc. entered into Asset Transfer Agreement with Autotelic Inc. (effective 2026-04-30).

“On April 30, 2026, the Company and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”)”

Oncotelic Therapeutics, Inc. entered into Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. valued at Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice (effective 2026-03-31).

“On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.”

Oncotelic Therapeutics, Inc. incurred convertible notes of $398,333.33 with Mast Hill Fund, LP at 10% per annum maturing the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a.

“On January 23, 2026, Oncotelic Therapeutics, Inc. (the "Company" or "Our") entered into a Securities Purchase Agreement (the "2026 Mast Hill Purchase Agreement "), with Mast Hill Fund, LP (" Mast Hill "), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the " 2026 Mast Hill Note ").”

Oncotelic Therapeutics, Inc. entered into 2026 Mast Hill Purchase Agreement with Mast Hill Fund, LP valued at $398,333.33 (effective 2026-01-23).

“On January 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the “ 2026 Mast Hill Note ”).”

Oncotelic Therapeutics, Inc. issued 44 units of unit to accredited investors.

“On December 31, 2025, Oncotelic Therapeutics, Inc. (the " Company ") completed entering into subscription agreements with certain accredited investors (" Subscription Agreement "), whereby the Company issued a total of 44 units (" Units ") to 22 accredited investors.”

Oncotelic Therapeutics, Inc. amended ICA with Jefferson Capital Ventures, LLC (effective 2025-12-31).

“On December 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into an amendment to an independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) dated August 6, 2025, for modifying the threshold of the first milestone contained within the ICA.”

Oncotelic Therapeutics, Inc. issued each Note convertible into up to 250,000 shares of Oncotelic's Common Stock of convertible note to 21 accredited investors for conversion price $0.10 per share.

“Each Note will be convertible into up to 250,000 shares of Oncotelic's Common Stock (conversion price $0.10 per share)”

Oncotelic Therapeutics, Inc. issued 250,000 Warrants per Unit of warrant to 21 accredited investors.

“Each Unit will also consist of 250,000 (the "Warrants") each to purchase one share of Oncotelic's Common Stock at $0.12 per share”

Oncotelic Therapeutics, Inc. issued 32 units of unit to 21 accredited investors for $25,000.00 per Unit.

“) unit s (th e “Units” ) bein g conducte d b y Maker . Each Unit consists of one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 12% and due and payable on the 2-year anniversary of the final closing of the Offering. Each Note will be convertible into up to 250,000”

Oncotelic Therapeutics, Inc. issued Each Unit consists of one note in the principal amount of $25,000, convertible into up to 250,000 shares of Common Stock or 25,000 shares of EdgePoint Common St of unit to accredited investors for $25,000 per Unit, or exchange of 2023 PPM Note.

“On December 4, 2025, Oncotelic Therapeutics, Inc. (the “ Company ”) completed entering into subscription agreements with certain accredited investors (“ Subscription Agreement ”), whereby the Company issued a total of 11 units (“ Units ”).”

Oncotelic Therapeutics, Inc. incurred convertible notes of $560,000 with Mast Hill Fund, LP at 10% per annum maturing earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep.

“On July 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2025 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $560,000 (the “ 2025 Mast Hill Note ”).”

Oncotelic Therapeutics, Inc.: Adopted new amended and restated by-laws containing new advance notice provisions for shareholder proposals and consent solicitations (effective 2023-05-18).

“On May 18, 2023, the Board of Directors of Oncotelic Therapeutics, Inc. (the “ Company ”) adopted the new amended and restated by-laws (the “ New By-Laws ”) for the Company, replacing the prior amended and restated by-laws. The New By-Laws contain new provisions for advance notices by shareholders to propose items for consideration at future Annual Meetings or Consent Solicitations.”

Seymour Fein was appointed as Chief Medical Officer at Oncotelic Therapeutics, Inc..

“Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.”

Fatih Uckun resigned as Chief Medical Officer at Oncotelic Therapeutics, Inc..

“On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.”

Seymour Fein was appointed as Consulting Chief Regulatory Officer at Oncotelic Therapeutics, Inc..

“In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.”

Fatih Uckun was appointed as Consulting Chief Medical Officer at Oncotelic Therapeutics, Inc..

“On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.”

David Diamond resigned as member of the Board at Oncotelic Therapeutics, Inc..

“On July 16, 2021, David Diamond notified the Board of Directors (the “ Board ”) of Oncotelic Therapeutics, Inc. (the “ Company ”) of his decision to resign, effective immediately, from his position as a member of the Board.”

Chulho Park resigned as Chief Technology Officer at Oncotelic Therapeutics, Inc..

“On July 1, 2021, Chulho Park, Ph. D., provided notice to the Company of his intention to resign as the Chief Technology Officer of the Company, to be effective immediately.”